BRIDGEWATER, N.J.--(BUSINESS WIRE)--Nov. 18, 2003--Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) announced today it will host a live webcast of its research and development forum, which is being held in New York City from 11:30 - 2:30 pm EST on Thursday November 20, 2003. Enzon scientists, as well as a noted clinician currently involved in an Enzon clinical trial, will present an update on the progress of Enzon’s clinical, as well as preclinical stage pipeline, and highlight its macromolecular engineering technologies. The live event can be accessed on the Internet at http://www.videonewswire.com/Enzon/112003. An archive of the event will also be available through November 27, 2003.
“Enzon has assembled a highly talented scientific team that within a short period of time, has established a robust pipeline of projects in all stages of development, which are being advanced effectively, efficiently, and rapidly, demonstrating high R&D productivity. This event will enable us to present data, update on our clinical findings, and provide the financial community with an overview of our expanding drug pipeline, as well as the technologies that will drive the expansion of our pipeline in the coming years,” stated Dr. Uli Grau, Enzon’s Chief Scientific Officer.
Enzon currently has two products that it plans to advance to pivotal stage clinical trials. The first is ATG-Fresenius S (Anti-T-Lymphocyte Immune Globulin or ATLI), which is a polyclonal antibody preparation used for the prevention of organ transplant rejection. The second product is PEG-Camptothecin, which is a topoisomerase I inhibitor that is being evaluated as a potential treatment for gastric and gastroesophageal junction cancers. Both of these important products will be discussed at Enzon’s R&D forum.
In addition, Dr Grau will be providing an overview of Enzon’s suite of Macromolecular Engineering technologies, and will discuss how these technologies add features that convert biomolecules into optimized pharmaceuticals. He will also discuss the projects that will lead to the filing of 2 or 3 INDs in 2004.
Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The company has developed or acquired a number of marketed products, including PEG-INTRON, marketed by Schering-Plough, and ABELCET, which is marketed in North America by Enzon. Enzon’s science-focused strategy includes an extensive drug development program that leverages the Company’s macromolecular engineering platform, including PEG modification and single-chain antibody (SCA(R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional products, projects, and technologies. Enzon has several drug candidates in various stages of development, independently and with partners.
Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. Actual results may vary significantly based upon a number of factors, which are described in the Company’s Form 10-K, Form 10-Q’s and Form 8-K’s on file with the SEC, including without limitation, Enzon’s ability to continue to increase ABELCET’s share of the antifungal market and to sustain such increased market share and to successfully market its proprietary products; Enzon’s dependence on Schering-Plough’s effective marketing of PEG-INTRON; Enzon’s ability to clinically advance its PEG-Camptothecin and ATG-Fresenius S programs; Enzon’s ability to sustain profitability and positive cash flow; risks in obtaining and maintaining regulatory approval for indications and expanded indications for Enzon’s products; market acceptance of and continuing demand for Enzon’s products; timing and results of clinical trials and the impact of competitive products and pricing. All information in this press release is as of November 18, 2003, and the Company undertakes no duty to update this information.
This release is also available at http://www.enzon.com
Contacts
Enzon Pharmaceuticals, Inc. Director Investor Relations Susan M. Mesco, 908-541-8678 or Media Relations: Euro RSCG Life NRP Mark R. Vincent, 212-845-4239
